Pacira BioSciences, Inc. (PCRX)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 100.00% | 72.64% | 70.11% | 74.10% | 72.12% |
| Operating profit margin | -10.47% | 12.99% | 9.00% | 24.20% | 11.01% |
| Pretax margin | -9.00% | 9.14% | 1.99% | 10.42% | 4.77% |
| Net profit margin | -14.20% | 6.22% | 2.39% | 7.75% | 34.58% |
Pacira BioSciences, Inc.'s gross profit margin has shown fluctuating trends over the years. It increased from 72.12% in 2020 to 74.10% in 2021, then decreased to 70.11% in 2022, before rising again to 72.64% in 2023, and significantly spiked to 100.00% in 2024. This spike in 2024 could be due to various factors like cost management or revenue recognition.
The operating profit margin exhibited a similar pattern of variability. It surged from 11.01% in 2020 to 24.20% in 2021, then dropped to 9.00% in 2022, increased to 12.99% in 2023, and then sharply declined to -10.47% in 2024. The negative operating profit margin in 2024 indicates that the company's operating expenses exceeded its operating income during that period.
The pretax margin also experienced fluctuations during the same period. It rose from 4.77% in 2020 to 10.42% in 2021, fell to 1.99% in 2022, increased again to 9.14% in 2023, and then turned negative at -9.00% in 2024. The negative pretax margin in 2024 suggests that the company incurred losses before accounting for taxes in that year.
Lastly, the net profit margin demonstrated inconsistent performance. It started at a high of 34.58% in 2020, dropped significantly to 7.75% in 2021, further declined to 2.39% in 2022, increased slightly to 6.22% in 2023, and then turned sharply negative at -14.20% in 2024. The negative net profit margin in 2024 indicates that after deducting all expenses, including taxes, the company experienced a net loss in that year.
Overall, Pacira BioSciences, Inc. has experienced significant fluctuations in its profitability ratios over the years, which can be attributed to various internal and external factors impacting its operations and financial performance.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -4.72% | 5.57% | 3.57% | 6.32% | 3.64% |
| Return on assets (ROA) | -6.41% | 2.66% | 0.95% | 2.02% | 11.42% |
| Return on total capital | -6.38% | 9.42% | 6.87% | 12.31% | 8.31% |
| Return on equity (ROE) | -12.79% | 4.82% | 2.05% | 5.75% | 23.48% |
Pacira BioSciences, Inc.'s profitability ratios show fluctuations over the years.
Operating Return on Assets (Operating ROA):
- The Operating ROA increased from 3.64% in 2020 to 6.32% in 2021, indicating an improvement in the company's ability to generate operating profits from its assets.
- However, there was a decline in Operating ROA to 3.57% in 2022, followed by a recovery to 5.57% in 2023.
- A significant decrease was observed in 2024, where the Operating ROA turned negative at -4.72%, potentially indicating operational challenges.
Return on Assets (ROA):
- The ROA was relatively high at 11.42% in 2020, but it sharply decreased to 2.02% in 2021, suggesting lower overall profitability relative to assets.
- The trend continued with ROA declining to 0.95% in 2022 before showing a modest improvement to 2.66% in 2023.
- In 2024, the ROA turned notably negative at -6.41%, signaling potential difficulties in generating profits from its total assets.
Return on Total Capital:
- Return on Total Capital increased from 8.31% in 2020 to 12.31% in 2021, indicating improved efficiency in generating returns for both debt and equity holders.
- However, this metric decreased to 6.87% in 2022 and further to 9.42% in 2023.
- Subsequently, in 2024, Return on Total Capital turned negative at -6.38%, reflecting a significant decline and potential challenges in utilizing total capital effectively.
Return on Equity (ROE):
- The ROE started at a robust 23.48% in 2020 but declined to 5.75% in 2021, indicating a lower return to equity holders.
- The trend of diminishing returns continued with ROE dropping to 2.05% in 2022 and a slight recovery to 4.82% in 2023.
- The most significant decline was seen in 2024, where the ROE turned notably negative at -12.79%, highlighting challenges in generating returns for equity investors.